摘要
探讨重组人血管内皮抑素注射液(恩度,YH-16)联合化疗治疗多种晚期恶性肿瘤的疗效及不良反应。20例经病理或细胞学检查确诊的恶性肿瘤患者,采用恩度联合化疗治疗,将恩度15mg加入NS250mL或500mL中匀速静脉滴入,d1～d14,同时联合化疗。每21d为1个周期。20例患者中,仅1例肺癌患者因经济受限仅完成1个周期的联合治疗,其余19例均完成2～6个周期的治疗,周期数为48个,平均2.5个。19例可评价患者中,PR3例,SD14例,PD2例,RR15.8%(3/19),疾病控制率89.5%(17/19)。生活质量改善13例,稳定3例,下降3例。G3/4毒副反应,主要有3例骨髓抑制,恶心呕吐及腹泻各1例。初步研究结果提示,恩度与化疗联合可以显著提高患者生活质量,并可提高疗效,毒副反应没有增加。
The objective of this study was to explore the efficacy and side-effect of rh-endostatin injection（YH-16,Endostar）combined with the chemotherapy on the multiple kinds of advanced malignancies.Endostar combined with chemotherapy was administrated to 20 malignant cases of stage Ⅲ-Ⅳ confirmed by histopathology or cytopathology.Fifteen mg endostar solved in 250 mL or 500 mL of normal saline was slowly intravenously dropped from day 1 to day 14,repeated after 7 days later.The chemotherapy agents were selected to be given simultaneously.The regimen was repeated every 21 days.One case with lung cancer only completed one cycle because of being short of money,the other 19 cases completed two or six cycles.Totally 48 cycles were completed and mean cycle was 2.5.Among 19 evaluable cases,there were 3 cases achieved PR,14 cases SD,and 2 cases PD.The objective response rate（RR）was 15.8%（3/19）,and disease control rate（DCR）was 89.5%（17/19）.The quality of life（QOL）improved in 13 cases（68.4%）,stabled in 3 cases（15.8%）,and decreased in 3 cases.The occurrence rates of G3/4 toxicities were low,including neutropenia（2/19）,thrombocytopenia（1/19）,nausea/vomiting（1/19）,and diarrhea（1/19）.In conclusion,the QOL of patients may improved significantly by endostar combined with chemotherapy and the side effects were not increased.
出处
《中华肿瘤防治杂志》
CAS
2008年第23期1835-1836,共2页
Chinese Journal of Cancer Prevention and Treatment
